Business Wire

3E

8.11.2023 15:01:35 CET | Business Wire | Press release

Share
3E in the Process of Acquiring French Workplace Safety Platform, Quick-FDS

Headquartered in Saint-Denis, France, Quick-FDS works with global manufacturers and users of chemical products, offering a full suite of solutions that enable improved regulatory compliance and workplace safety. Specifically, the Company’s highly specialized regulatory expertise and mission critical Safety Data Sheet (“SDS”) offering allows many of the world’s largest companies to comply with both local and global regulatory pressures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231106497017/en/

“Quick-FDS is known globally for its strong commitment to chemical safety and deep understanding of the French market, which is a market of particular importance to 3E and a country in which we would be pleased to expand our operations,” said Greg Gartland, Chief Executive Officer of 3E. “Bringing Quick-FDS and 3E together would solidify the combined company as the global leader in SDS management, with the goal of empowering clients to improve chemical and workplace safety.”

Increasingly complex regulations in the chemical industry put a significant burden on companies with global operations, including REACH regulations in the EU requiring all suppliers of chemicals to systematically dispatch Safety Data Sheets for each chemical substance to their customers. Quick-FDS’ market-leading solution enables superior regulatory compliance and efficiency, allowing customers to focus on their business instead of navigating ever-changing regulations. With over 600 customers, including many of the world’s leading users and suppliers of chemicals, Quick-FDS plays a pivotal role in ensuring compliance in France and globally.

Robin Dualé, President of WEKA in France, said “The combination of 3E and Quick-FDS would unite two of the most sophisticated SDS management solutions globally. This combination would provide customers worldwide with the ability to make informed decisions to reduce regulatory risks consistently, efficiently, and confidently.”

“Continued expansion of 3E’s footprint in the European Market via strategic acquisitions represents a core tenet of 3E’s growth strategy,” added JP O'Sullivan, Chief Operating Officer at 3E. "By seeking to bring together the strengths of 3E and Quick-FDS, we are not only aiming to expand our global reach but also reinforce our commitment to offering safety and compliance solutions to our customers. This move would enable us to provide even greater value by harnessing the strengths of both organizations. The addition of Quick-FDS would extend 3E's market-leading SDS Catalog, with the combined company providing more than 10 million SDS' to customers around the world."

Quick-FDS would represent 3E’s second acquisition since its separation from Verisk in March 2022.

Shearman & Sterling LLP and Proskauer Rose LLP serve as the legal advisors to 3E. WEKA Group and Quick-FDS are advised by Carlsquare (M&A) and Astura (Legal).

The transaction would be subject to customary conditions including the prior staff representatives’ consultation and regulatory approvals.

About Quick-FDS

Quick-FDS provides digital workflow solutions related to Safety Data Sheet management to help manufacturers and end-users along the full supply chain for chemical products comply with global regulations, including European REACH. Quick-FDS’ historical success is driven by tight integration with compliance-related workflows throughout the chemical and specialty materials sector. Global chemical manufacturers, distributors, and wholesalers strongly endorse Quick-FDS as a true partner within their broader regulatory strategy.

About 3E

For more than 35 years the world’s leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world’s largest chemical manufacturers, retailers and pharmaceutical companies. Learn more at www.3ECo.com.

About WEKA Group

WEKA Group is a diversified group of media companies and a leading provider of specialist information and advanced education with 15 operational companies in Germany, Austria, and France. WEKA Group’s media-neutral content is offered in all common formats and reaches highly diversified niche markets across all industries. WEKA Group is headquartered in Kissing, Germany, and employs approximately 1,000 employees.​​​​​​​

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231106497017/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye